Leveraging the Imagia Canexia Health Insights Platform (ICHIP), now Canadian oncologists can deliver precision cancer treatments to patients no matter where they live
MONTRÉAL, July 27, 2022 – Imagia Canexia Health (ICH), a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions, today announced that Health Canada now permits ICHIP—held under ICH’s Imagia Healthcare subsidiary—to be manufactured and deployed across Canada. Imagia Canexia Health offers a unique clinical solution for oncologists to quickly generate reports, which includes therapeutic and clinical trial recommendations. The ICHIP furthers their ability by providing intricate molecular and computational genome analysis, from targeted next-generation sequencing (NGS) data, for individual cancer patients. This new approval advances Imagia Canexia Health’s mission to combine groundbreaking genomics, oncology, artificial intelligence, and informatics so health systems can provide cost-effective
Clinicians receive next-generation sequencing (NGS) data sourced from human tissue or blood samples. These insights are collected, as well as processed, on Illumina’s NextSeq and MiSeq devices. Then, ICHIP uses AI to detect and analyze genomic variants, match interpretations, identify potential clinical trials, as well as generate a cancer-treatment results report to augment treatment decisions by oncologists. This information is used in conjunction with other clinical and diagnostic findings to make the most informed care-management decisions.
“The ability to now implement ICHIP locally at our Cancer Center means clinicians will have a report informed by the clinical context, creating even more robust real-time-data insights to support their expertise,” said Dr. Bryan Lo, the Medical Director, Molecular Oncology Diagnostics Lab, at The Ottawa Hospital and Eastern Ontario Regional Laboratory Association, who is currently using ICH’s software to report out liquid biopsy cases. “Cancer is a constant fight against time, and novel technology like the ICHIP which helps make faster decisions is invaluable to our patients’ lives.”
“ICH is proud of our Health Canada Medical Device Establish License, as it is important for commercializing ICHIP, which can now be manufactured and distributed across the country,” said Imagia Canexia Health CEO Geralyn Ochab. “This milestone reinforces ICH’s commitment to having our products reach patients and improve Canadian’s lives.”
About Imagia Canexia Health
Imagia Canexia Health (ICH) is a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions. Leveraging AI-based informatics for treatment selection and monitoring, oncologists now have leading clinical decision support right at their fingertips. With a network of over 20 hospitals and reference labs worldwide, ICH ensures that doctors have the right insights to deliver cost-effective cancer testing to patients no matter where they seek treatment. Join ICH in
closing the health-equity gap in cancer: imagiacanexiahealth.com
June 15, 2022
Imagia Canexia Health Achieves First CE-IVD Status in the E.U. to Deploy Comprehensive Cancer Testing Platform
MONTRÉAL, June 15, 2022 – Imagia Canexia Health, a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions, today announced the CE-IVD marking for its Imagia Canexia Health Insights Platform (ICHIP) to operate across Europe.
June 3, 2022
This article from BioWorld Medtech includes an interview with our CMO David Huntsman, where he discusses Imagia Canexia Health's Candetect project, which is developing precision oncology software that will help monitor resistance to cancer therapy and treatment relapse in individual cancer survivors.